drugset / Trial / NCT00741637
Safety and Immunogenicity of Single Dose Choleragarde® in HIV-Seropositive Adults
Phase 2
Completed
32 enrolled
International Vaccine Institute
Siriraj Hospital · collabVaccine Technologies Inc. · collab
RandomizedParallel-groupQuadruple-blindPrevention
Summary
The purpose of this study is to assess the safety and immunogenicity of Peru-15 (CholeraGarde®) vaccine in HIV seropositive adult population of Bangkok Thailand
Timeline
- Start
- 2010-07
- Primary completion
- 2011-04
- Completion
- 2011-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CholeraGarde® | Vaccine | 5e+07 unknown | Oral |
| Subject | CholeraGarde® | Vaccine | 1e+09 unknown | Oral |